Richard A. Bermudes, MD, is a distinguished psychiatrist and the Chief Medical Officer of BrainsWay. BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. BrainsWay’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology is FDA-cleared to treat major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction.
Dr. Bermudes is the founder and president of Empathy MindCare, a healthcare organization that integrates rapid-acting treatments like Deep TMS and Ketamine with evidence-based psychotherapies to address mental health conditions such as depression, anxiety, PTSD, and addiction. Additionally, he founded Empathy Minded, an education technology platform dedicated to advancing mental health care through education, community, and support. He is the lead editor of Transcranial Magnetic Stimulation, Second Edition.
We now have the ability to diagnose and treat with data-driven insights and deliver measurable outcomes. It’s on us as providers to ensure that we are consistently adopting the latest, proven technology and treatment modalities that can benefit our patients.